L’Oréal is doubling its stake in Galderma to 20%, buying shares from EQT-led investors as it deepens its push into skincare drugs https://t.co/d6WcvIZ6IV ...

Core Viewpoint - L'Oreal has increased its stake in Galderma to 20% by acquiring an additional 10% stake in the dermatology firm [1] Company Summary - L'Oreal, a French cosmetics group, has made a strategic investment in Galderma, a dermatology company, by purchasing a further 10% stake [1] - This acquisition raises L'Oreal's total ownership in Galderma to 20%, indicating a strong commitment to expanding its presence in the dermatology sector [1] Industry Summary - The move reflects a growing trend in the cosmetics industry where companies are diversifying their portfolios to include dermatological products, which are increasingly in demand [1]

Core Insights - L'Oréal has announced the acquisition of an additional 10% stake in Galderma, increasing its total ownership to 20% [1][2] - The transaction is part of L'Oréal's strategy to strengthen its position in the fast-growing aesthetics market [3][4] - Galderma's board will consider nominating two non-independent board candidates from L'Oréal following the 2026 Annual General Meeting [2] Company Strategy - L'Oréal's increased investment in Galderma reflects its commitment to the aesthetics sector, which is seen as a key adjacency to its core beauty business [3][4] - The partnership aims to enhance scientific collaboration between L'Oréal and Galderma, leveraging their complementary expertise [4] Transaction Details - The acquisition will be executed through an off-market block trade with a consortium led by EQT [5] - The transaction will be funded using L'Oréal's available cash and credit lines, with closing expected by Q1-2026, pending regulatory approvals [6] Company Background - L'Oréal is a leading player in the beauty industry, generating sales of €43.48 billion in 2024 and employing over 90,000 people globally [8] - Galderma is a leader in dermatology, operating in approximately 90 countries and focusing on innovative, science-based products [10]

Core Insights - Partners Group Private Equity (LSE: PEY) is preparing for a significant shareholder-return program due to successful exits generating fresh capital [1] Financial Performance - PEY recorded €65.4 million (approximately $76.4 million) in distributions during the first nine months of 2025, with a strong outlook for continued performance [2] - The firm is on track to achieve around €200 million ($233 million) in exit proceeds for both 2025 and 2026, which could facilitate substantial buybacks [3] Portfolio Strength - The underlying portfolio has seen valuations increase by over 10% year-on-year, driven by double-digit EBITDA growth and improved multiples across key holdings [4] - Recent public listings, such as those of Vishal Mega Mart and Galderma, have contributed positively to PEY's valuation gains [4] Buyback Strategy - Buybacks are considered an effective use of excess capital for listed private-equity vehicles, especially when shares are trading below NAV [5] - PEY may initiate a buyback program in early 2026, contingent on the completion of sales and capital allocation decisions [6] Shareholder Impact - If buybacks occur at the higher end of expectations, shareholders could experience an increase in NAV per share and a reduction in the current discount to NAV [7]

Summary of Evolus Conference Call Company Overview - Evolus is currently in a significant growth phase, having launched its second product, Evolysse, alongside its flagship product Jeuveau, which has established a strong market presence in the U.S. and Europe [2][3][4] Key Points and Arguments Product Development and Market Position - Jeuveau has been recognized as the fastest-growing brand in the U.S. aesthetic market, capturing mid-teens market share, marking the first time a company has achieved double-digit market share since the entry of the first two players [2][4] - Evolysse is positioned as a differentiated product utilizing new technology (COLDEX) for hyaluronic acid (HA) production, with plans to introduce a sculpt product for the mid-face in the upcoming year [3][4][22] - The company has built a customer base of 17,000 clinics across the U.S., which presents significant growth opportunities as it enters the second phase of commercialization [3][4] Market Dynamics and Performance - Despite a challenging macroeconomic environment, Evolus has reported double-digit growth, with Jeuveau continuing to grow in the U.S. and strong international performance, particularly in the U.K. [4][5][48] - The aesthetic market, particularly for neuromodulators, has historically shown resilience during economic downturns, although current conditions are presenting unique challenges [6][7][8] - The company anticipates a rebound in the market, driven by pent-up consumer demand, as consumers are currently delaying treatments due to economic pressures [8][9] Competitive Landscape - The competitive landscape includes established players like AbbVie and Galderma, with Evolus focusing on differentiating its products through quality and innovative marketing strategies [6][7][9] - Evolus has successfully positioned Jeuveau against Botox through head-to-head clinical trials, demonstrating superior efficacy in multiple endpoints [12][13][14] Consumer Trends and Marketing Strategy - There is a growing consumer trend towards preventive aesthetic treatments, with younger demographics increasingly seeking these services [7][8] - Evolus has launched a campaign to rebrand HA fillers, moving away from the term "filler" to "injectable HA," which has resonated positively with consumers [29][30] - The company is leveraging its loyalty program to encourage repeat purchases and cross-selling between Jeuveau and Evolysse [19][22] Financial Outlook and Business Development - Evolus has access to $100 million in capital for business development, with a focus on achieving profitability by the fourth quarter of 2025 and for the full year of 2026 [41][42][48] - The company expects to see sequential improvement in performance as it wraps around a depressed market base, with a strong international growth trajectory anticipated [46][47][48] Future Product Pipeline - The introduction of the Skulpt product is expected in the second half of 2026, which will complement the existing HA product line and enhance the company's market position [46][47] - Evolus is exploring opportunities in biostimulators and other innovative products to expand its portfolio [43][44] Additional Important Insights - The company has successfully reduced expenses by $25 million, positioning itself for profitability amidst a declining market [48] - Evolus is focused on building partnerships with clinics, emphasizing the importance of training and support for product adoption [20][21][25] This summary encapsulates the key insights from the Evolus conference call, highlighting the company's strategic direction, market dynamics, and future growth potential.

Core Viewpoint - Galderma raised its full-year guidance after third-quarter sales exceeded expectations, leading to a 7% increase in share price [1][2] Group 1: Financial Performance - Third-quarter net sales reached $1.29 billion, surpassing the consensus estimate of $1.24 billion [1] - Full-year net sales are now expected to grow between 17% and 17.7% year-on-year at constant currency, an increase from the previous forecast of 12% to 14% [2] - The forecast for core EBITDA margin has been adjusted to between 23.1% and 23.6% at constant currency, up from about 23% previously [4] Group 2: Market Dynamics - The U.S. market saw a 17.5% increase in third-quarter net sales compared to the same quarter last year [3] - Despite facing a 39% import duty imposed by the U.S. government, Galderma's performance remains strong, prompting the company to increase employment in the U.S., Europe, and Asia [3] Group 3: Strategic Focus - Galderma is focusing on the U.S. market due to its strong growth potential and plans to invest over $650 million in U.S. manufacturing through 2030 [2] - The company is experiencing robust growth in its Nemluvio dermatology portfolio, contributing to its overall performance [2][3]

Core Viewpoint - The Stockholm Stock Exchange is currently the leading market in Europe for initial public offerings (IPOs), raising nearly $2 billion in 2025, significantly outperforming other major financial hubs like London, Frankfurt, and Madrid [1][2]. Group 1: Market Performance - Companies listed in Sweden have raised nearly $2 billion in 2025, which is more than eight times the volume seen in London [1]. - The IPO activity in Sweden is highlighted by upcoming high-profile listings from Verisure and NOBA, indicating a robust market environment [2]. - Despite the current boom, the amount raised in 2025 is still far from the all-time peak of over $11.5 billion achieved in 2021 [17]. Group 2: Investment Culture - Sweden's success in the IPO market is largely attributed to a strong national "equity culture," with about 70% of household wealth held in equity, compared to the EU average of 59% [5]. - A significant portion of the population, approximately seven in ten residents, hold investment funds directly, with only about 10% of their financial assets in cash or bank deposits, the lowest in Europe [5][6]. - The cultural acceptance of equity investment is supported by decades of government policy and regulation, fostering a mature investment ecosystem [6][7]. Group 3: Ecosystem and Support - The local capital ecosystem in Sweden is characterized by a high participation of retail and family office investors, as well as institutional capital managing savings and pension assets [8]. - The efficient IPO process benefits from a consistent deal flow and the involvement of "cornerstone" investors, which provides early quality assurance for new public offerings [10][11]. - A steady supply of companies backed by private equity and venture capital is contributing to the pipeline of potential IPOs, with private equity firms ensuring their portfolio companies are "IPO-ready" [12][14]. Group 4: Future Outlook - The outlook for the IPO market in Sweden remains positive, with expectations for a significant increase in activity in 2026 across the Nordics [18]. - Investors are currently selective, focusing on track records and prospects for profitable growth, but confidence in the upcoming pipeline is strong [17][18].

Core Insights - Galderma, a leader in the dermatology category, will present updates from its portfolio at the 34th European Academy of Dermatology and Venereology (EADV) congress in Paris from September 17-20, 2025 [1] - The company is committed to addressing various skin conditions and will showcase 12 abstracts, including data on sensitive skin, prurigo nodularis, and atopic dermatitis [1] Company Focus - Galderma emphasizes its dedication to dermatology by participating in significant industry events like the EADV congress [1] - The presentation of 12 abstracts indicates a robust research and development pipeline aimed at enhancing treatment options for skin conditions [1]

Summary of Key Points from Conference Call Industry Overview - The macroeconomic environment is characterized by all-time highs in global markets, but underlying issues are emerging, particularly in the U.S. and Europe [1][2] - The divergence between headline index performance and investor performance is notable, with market-neutral and systematic quant strategies facing challenges [3][4] Macro Insights - Upcoming Federal Reserve decisions and employment data are expected to influence interest rates, consumer behavior, and inflation trends [5][6] - Inflation is becoming a pressing concern, with recent CPI data indicating rising prices in various consumer sectors, including household goods and clothing [19][20] Micro Insights - Major tech companies like Microsoft, Meta, Apple, and Amazon are set to report earnings, which will significantly impact market sentiment and AI capital expenditure expectations [5][6] - The recent profit warning from Novo Nordisk, resulting in a ~25% stock drop, highlights the volatility in crowded stocks [5][6] Trade and Tariff Developments - Trade deals, particularly with Japan and Europe, have had mixed responses, revealing structural pain points in industries like automotive [9][10] - The removal of uncertainty regarding tariffs has shifted focus from fear of rates to the actual costs of tariffs, affecting prices, margins, and earnings [9][10] Currency and FX Impacts - The U.S. dollar is experiencing its weakest start to a year in 50 years, impacting earnings for both U.S. and European companies [11][12] - Currency fluctuations are expected to be a significant factor in the upcoming earnings season, alongside tariff impacts [11][12] M&A and Market Activity - There is a potential resurgence in M&A activity as geopolitical concerns and macroeconomic headwinds ease, with a focus on scale, geographical exposure, and diversification [15][16] - Recent IPOs, such as Galderma, have shown strong performance post-listing, indicating a healthy appetite for quality assets [16][17][18] Valuation Trends - The return of unicorns and AI-related startups is noted, with significant value creation in private markets [18] - Recent IPOs have created substantial value for investors, with some companies seeing stock price increases of 100% to 300% since listing [18] Risks and Concerns - There are concerns about retail euphoria and the potential for a market correction, particularly if inflation continues to rise and long-term bond yields break out [7][8] - The social and employment impacts of AI advancements are less discussed but pose significant risks for workforce transitions [7][8] Conclusion - The market is navigating a complex landscape of macroeconomic indicators, corporate earnings, and geopolitical developments, with a cautious outlook on inflation and potential market corrections ahead.

Core Viewpoint - The global botulinum toxin market is projected to reach $15.8 billion by 2031, with a compound annual growth rate (CAGR) of 7.7% in the coming years [4]. Market Overview - The botulinum toxin is produced by Clostridium botulinum and is widely used in both medical and aesthetic applications due to its muscle-relaxing properties [1]. - The market is primarily driven by the increasing demand for anti-aging and cosmetic treatments, as well as the expanding medical applications for various conditions [15]. Market Size and Growth - The botulinum toxin market is expected to grow significantly, with the aesthetic segment accounting for approximately 58.3% of the total demand [10]. - The most common product type is the 50-unit formulation, which holds about 43.5% market share [8]. Key Players - Major manufacturers in the global botulinum toxin market include AbbVie, Galderma, Ipsen, and Daewoong, with the top four companies holding around 90% of the market share in 2024 [7]. Challenges - The market faces challenges such as intense competition, regulatory scrutiny, and concerns regarding safety and side effects, which may hinder growth [16]. Future Trends - The market is expected to see diversification and technological advancements, with a focus on personalized aesthetic solutions and the integration of botulinum toxin with other treatments [15][17].